Gain Therapeutics, Inc.
GANXHealthcare|Biotechnology|US
$1.03
+0.07 (+7.25%)
DCF Value
$0.61
Tangible Book / Share
$0.26
Cash / Share
$0.31
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06732180 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease | Parkinson Disease | P1 | Recruiting | 20 | Open-label | GT-02287 |
| NCT06325800 GlycOxiTOD: Multimodal Vascular and Target-Organ Damage Registry | Hypertension, Target Organ Damage | Recruiting | 1,000 | — | — | |
| NCT06569628 Validation of a Life Stories Methodologies in Long-Term Care Centres | Long-term Care Centres for Old Adults Users, Relatives of Long-term Care Centres for Old Adults Users | N/A | Active | 378 | Single-blind | — |
| NCT07280299 Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease | Parkinson Disease | P2 | Not Yet Recruiting | 111 | RCT, Double-blind | Low Dose GT-02287, High Dose GT-02287, Placebo |
| NCT02402985 Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics | Diabetes Mellitus, Type 2, Nutrition Disorders | N/A | Completed | 44 | RCT, Open-label | — |